Compare Gilead Sciences, Inc. (GILD) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Manhattan Associates Inc — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Manhattan Associates Inc trades at $204.89 (market cap $12.06B). The key difference: Gilead Sciences, Inc. is far larger — about 15.1× Manhattan Associates Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Manhattan Associates Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Manhattan Associates Inc for 12 Days on average.
| GILD | MANH | |
|---|---|---|
Market Cap | $182.40B | $12.06B |
Volume | 4,469,821 | 376,150 |
Sector | Health | Technology |
52-Week High | $155.80 | $223.76 |
52-Week Low | $117.18 | $120.88 |
Typical Hold Time | 111 Days | 12 Days |
Enterprise Value | $205.46B | $11.93B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, showing modest daily gains of 0.17% with strong technical support at $145. The company demonstrates robust fundamentals with Q2 2026 earnings beating expectations despite a net loss, while maintaining a high gross margin of 79.59%. Recent developments include expanded HIV prevention drug access across Latin America through a PAHO partnership, positioning the company for growth in key therapeutic areas.
GILD presents a mixed outlook with strong analyst support (65.5% buy ratings) and a $151.57 price target offering 3% upside, but faces headwinds from negative net income margins and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, though investors should monitor the company's ability to translate top-line strength into sustainable profitability amid competitive pressures.
MANH trades at $206.78, up 2.31% today, with a bullish technical outlook as it sits above key support at $205. The company shows strong profitability with a net margin of 18.67% and has beaten earnings estimates for three consecutive quarters. Recent news includes a product launch of Editions for its solutions but also ongoing legal investigations into fiduciary duties.
The outlook is cautiously optimistic given analyst consensus of Buy and a $210.50 price target, though high valuation ratios and legal overhangs present risks. Earnings growth remains the key catalyst for further upside, but investors should weigh the elevated P/E of 59.26 against potential legal and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
